MA34609B1 - Composé de cyclopropane - Google Patents

Composé de cyclopropane

Info

Publication number
MA34609B1
MA34609B1 MA35823A MA35823A MA34609B1 MA 34609 B1 MA34609 B1 MA 34609B1 MA 35823 A MA35823 A MA 35823A MA 35823 A MA35823 A MA 35823A MA 34609 B1 MA34609 B1 MA 34609B1
Authority
MA
Morocco
Prior art keywords
hydrogen atom
atom
independently
antagonist activity
orexin receptor
Prior art date
Application number
MA35823A
Other languages
English (en)
Inventor
Taro Terauchi
Ayumi Takemura
Takashi Doko
Yu Yoshida
Toshiaki Tanaka
Keiichi Sorimachi
Yoshimitsu Naoe
Carsten Beuckmann
Yuji Kazuta
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA34609B1 publication Critical patent/MA34609B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

)LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (A) [DANS LAQUELLE Q REPRÉSENTE -CH- OU UN ATOME D'AZOTE ; R1A ET R1B REPRÉSENTENT INDÉPENDAMMENT UN GROUPE ALKYLE EN C1 À C6 OU ANALOGUES ; R1C REPRÉSENTE UN ATOME D'HYDROGÈNE OU ANALOGUES ; R2A, R2B, R2C ET R2D REPRÉSENTENT INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN ATOME D'HALOGÈNE OU ANALOGUES ; R3A, R3B ET R3C REPRÉSENTENT INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN ATOME D'HALOGÈNE OU ANALOGUES ; ET R3D REPRÉSENTE UN ATOME D'HYDROGÈNE OU ANALOGUES] OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, POSSÉDANT UNE ACTIVITÉ ANTAGONISTE SUR UN RÉCEPTEUR DE L'OREXINE ET POUVANT DONC ÊTRE UTILISÉ EN TANT QU'AGENT THÉRAPEUTIQUE POUR DES TROUBLES DU SOMMEIL, TELS QUE L'INSOMNIE, SUR LESQUELS L'ACTIVITÉ ANTAGONISTE SUR UN RÉCEPTEUR DE L'OREXINE EST EFFICACE.
MA35823A 2010-09-22 2011-09-20 Composé de cyclopropane MA34609B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38534210P 2010-09-22 2010-09-22
JP2010211629 2010-09-22
PCT/JP2011/071325 WO2012039371A1 (fr) 2010-09-22 2011-09-20 Composé de cyclopropane

Publications (1)

Publication Number Publication Date
MA34609B1 true MA34609B1 (fr) 2013-10-02

Family

ID=45873858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35823A MA34609B1 (fr) 2010-09-22 2011-09-20 Composé de cyclopropane

Country Status (29)

Country Link
US (1) US8268848B2 (fr)
EP (1) EP2626350B1 (fr)
JP (1) JP4944286B1 (fr)
KR (1) KR101458007B1 (fr)
CN (1) CN103153963B (fr)
AR (1) AR083060A1 (fr)
AU (1) AU2011304285B2 (fr)
BR (1) BR112013006594B1 (fr)
CA (1) CA2811895C (fr)
CL (1) CL2013000784A1 (fr)
DK (1) DK2626350T3 (fr)
ES (1) ES2540851T3 (fr)
IL (1) IL225437A (fr)
JO (1) JO2990B1 (fr)
MA (1) MA34609B1 (fr)
MX (1) MX2013003218A (fr)
MY (1) MY160969A (fr)
NZ (1) NZ609313A (fr)
PE (1) PE20131162A1 (fr)
PH (1) PH12013500490A1 (fr)
PL (1) PL2626350T3 (fr)
PT (1) PT2626350E (fr)
RS (1) RS54101B1 (fr)
RU (1) RU2571414C2 (fr)
SG (1) SG188585A1 (fr)
SI (1) SI2626350T1 (fr)
TW (1) TWI516484B (fr)
UA (1) UA108510C2 (fr)
WO (1) WO2012039371A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6147279B2 (ja) * 2012-02-17 2017-06-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 オレキシン−２受容体アンタゴニストの合成において有用な方法および化合物
EP2922823B1 (fr) * 2012-11-20 2018-10-31 Merck Sharp & Dohme Corp. Inhibiteurs pyrimidines de pde10
CN107074780B (zh) * 2014-08-06 2020-06-12 卫材R&D管理有限公司 用于生产嘧啶-1-醇化合物及其中间体的方法
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
SG11201803191VA (en) 2015-10-29 2018-05-30 Univ Tsukuba Morphinan derivative and medical usage thereof
CA3022068A1 (fr) 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methodes de traitement de troubles du rythme circadien
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
TW202432509A (zh) * 2019-05-15 2024-08-16 日商衛材R&D企管股份有限公司 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
US12534448B2 (en) 2019-12-11 2026-01-27 Tapi Czech Industries S.R.O Solid state form of lemborexant
MX2022007304A (es) 2019-12-20 2022-08-22 Eisai R&D Man Co Ltd Uso de lemborexant para tratamiento del insomnio.
US20230103250A1 (en) * 2020-01-16 2023-03-30 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
WO2021205648A1 (fr) * 2020-04-10 2021-10-14 国立大学法人東海国立大学機構 Procédé objectif d'évaluation du sommeil pour un patient souffrant d'un trouble mental
US20250064802A1 (en) 2021-07-26 2025-02-27 Eisai R&D Management Co., Ltd. Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN118871427A (zh) * 2022-03-25 2024-10-29 浙江华海药业股份有限公司 一种莱博雷生及其中间体的制备方法
WO2023178702A1 (fr) * 2022-03-25 2023-09-28 浙江华海药业股份有限公司 Procédé de préparation de lemborexant et procédé de préparation d'un composé intermédiaire pour le lemborexant
CN117384082A (zh) * 2022-07-20 2024-01-12 杭州国瑞生物科技有限公司 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷的合成方法
CN117050044A (zh) * 2022-07-27 2023-11-14 南方科技大学 高光学纯度的环丙烷类化合物及其制备方法和用途
CN117466890A (zh) * 2023-10-31 2024-01-30 安徽美诺华药物化学有限公司 一种抗血栓栓塞性疾病药物中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (fr) 1995-05-05 1999-01-20 Human Genome Sciences Inc Recepteur de neuropeptides humain
PT1027043E (pt) * 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
JP2008513434A (ja) * 2004-09-23 2008-05-01 ファイザー・プロダクツ・インク トロンボポイエチン受容体アゴニスト
CN101155792A (zh) * 2005-04-12 2008-04-02 默克公司 氨基丙氧基苯基增食欲素受体拮抗剂
WO2006110626A1 (fr) * 2005-04-12 2006-10-19 Merck & Co., Inc. Antagonistes du récepteur de l’orexine de type amidopropoxyphényle
JP2006328057A (ja) * 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (fr) 2006-05-10 2007-11-15 Pfizer Japan Inc. Composé de cyclopropanecarboxamide
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
BRPI0716532A2 (pt) 2006-09-11 2013-09-24 Glaxo Group Ltd compostos azabicÍclios como inidores de reabsorÇço de monoaminas
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
MX2010002419A (es) 2007-09-21 2010-03-30 Sanofi Aventis (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP2012510494A (ja) * 2008-12-02 2012-05-10 グラクソ グループ リミテッド Ｎ−｛［（ｉｒ、４ｓ、６ｒ）−３−（２−ピリジニルカルボニル）−３−アザビシクロ［４．１．０］ヘプタ−４−イル］メチル｝−２−ヘテロアリールアミン誘導体およびその使用
US20120165339A1 (en) * 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives

Also Published As

Publication number Publication date
EP2626350A4 (fr) 2014-02-12
KR101458007B1 (ko) 2014-11-04
DK2626350T3 (en) 2015-06-29
CA2811895A1 (fr) 2012-03-29
RU2013117464A (ru) 2014-10-27
US8268848B2 (en) 2012-09-18
PH12013500490A1 (en) 2013-05-06
BR112013006594A2 (pt) 2016-06-21
RU2571414C2 (ru) 2015-12-20
JO2990B1 (ar) 2016-09-05
EP2626350B1 (fr) 2015-04-15
IL225437A0 (en) 2013-06-27
CL2013000784A1 (es) 2013-07-05
MY160969A (en) 2017-03-31
PT2626350E (pt) 2015-08-03
UA108510C2 (xx) 2015-05-12
BR112013006594B1 (pt) 2021-08-17
TWI516484B (zh) 2016-01-11
AU2011304285B2 (en) 2015-01-29
AR083060A1 (es) 2013-01-30
AU2011304285A1 (en) 2013-05-16
IL225437A (en) 2015-05-31
PE20131162A1 (es) 2013-10-19
MX2013003218A (es) 2013-06-28
JP4944286B1 (ja) 2012-05-30
JPWO2012039371A1 (ja) 2014-02-03
PL2626350T3 (pl) 2015-08-31
ES2540851T3 (es) 2015-07-14
US20120095031A1 (en) 2012-04-19
SG188585A1 (en) 2013-04-30
CA2811895C (fr) 2015-12-08
NZ609313A (en) 2014-05-30
TW201305129A (zh) 2013-02-01
EP2626350A1 (fr) 2013-08-14
CN103153963B (zh) 2014-12-24
KR20130097776A (ko) 2013-09-03
WO2012039371A1 (fr) 2012-03-29
CN103153963A (zh) 2013-06-12
SI2626350T1 (sl) 2015-09-30
RS54101B1 (sr) 2015-10-30

Similar Documents

Publication Publication Date Title
MA34609B1 (fr) Composé de cyclopropane
MX2010004232A (es) Compuesto de indolina de pirimidilo.
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
RU2502730C2 (ru) Сульфонамидные соединения и их применение
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
BR112015020545A2 (pt) derivado de tetraidroimidazo[1,5-d][1,4]oxazepina
PE20081609A1 (es) Compuestos carboxamida y su uso como inhibidores de calpaina
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
EA201100698A1 (ru) Производные тиенотриазолодиазепина, активные в отношении апо а1
MA31118B1 (fr) Procede de preparation d'un derive de benzimidazole
PE20080234A1 (es) Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
BR112013017302A2 (pt) formulações de imunossupressor
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
BR112014009927A2 (pt) "derivado de azol, composição farmacêutica que o compreende e uso do mesmo"
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
MA38275A1 (fr) Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA38659B1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété